Alvelestat

Mereo BioPharma announces CEO Dr. Denise Scots-Knight's presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The company focuses on rare diseases with candidates like setrusumab for osteogenesis imperfecta and alvelestat for AATD-LD, alongside oncology candidates. Partnerships and designations aim to advance treatments, with forward-looking statements highlighting potential risks and uncertainties.

Mereo BioPharma announced CEO Dr. Denise Scots-Knight will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025. The presentation will be webcast live and archived on the company's website. Mereo focuses on rare diseases, with key products setrusumab and alvelestat, and has partnerships for development and commercialization.

Mereo BioPharma, a biopharmaceutical company specializing in rare diseases, announced CEO Dr. Denise Scots-Knight's presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The company focuses on innovative therapeutics, including setrusumab for osteogenesis imperfecta and alvelestat for AATD-LD, with partnerships and designations from regulatory bodies. Mereo also explores oncology treatments and has global licensing agreements for its product candidates.

Mereo BioPharma Group plc, a $579M market cap biopharma, focuses on rare diseases like osteogenesis imperfecta (OI) and alpha-1 antitrypsin deficiency (AATD)-associated lung disease. Setrusumab, its lead asset for OI, shows promising Phase 2 results, with potential sales exceeding $750M. Alvelestat, targeting AATD, has encouraging Phase 2 data, paving the way for Phase 3 studies. With $81M in cash, Mereo's financial position supports operations into 2026/2027, and potential partnerships could enhance its financial flexibility. Analysts project significant market opportunities and upside potential for Mereo's stock.